Excessive sleepiness (somnolence)
Also known as: Somnolence
Methodology & AI Transparency ⓘ
Excessive sleepiness (somnolence) Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: Excessive sleepiness (somnolence) (also termed Somnolence)—coded clinically as R40.0 across Sleep Disorders guidelines—combines CBT-I behavioral sleep in Excessive sleepiness (somnolence) (R40.0: efficiency tracking) with structured follow-up of Apnea-Hypopnea Index (AHI) [Excessive sleepiness (somnolence) R40.0] (< 5 events/hour (R40.0)).
- 2 Real-world patient consensus: Clinical coding for Excessive sleepiness (somnolence) uses ICD-10 R40.0 across Sleep Disorders specialty care.
- 3 Typical cash cost range: Workup highlights for Excessive sleepiness (somnolence) (R40.0): CBT-I behavioral sleep in Excessive sleepiness (somnolence) (R40.0: efficiency tracking).
- 4 Top reported side effects / signs: Objective lab/clinical target for Excessive sleepiness (somnolence): Serum Ferritin (Restless in Excessive sleepiness (somnolence) (R40.0: Legs)) (> 75 ng/mL (R40.0)) and Apnea-Hypopnea Index (AHI) [Excessive sleepiness (somnolence) R40.0].
Ask our AI Specialists anything about Excessive sleepiness (somnolence)
What Is Excessive sleepiness (somnolence)?
Excessive sleepiness (somnolence) (also termed Somnolence)—coded clinically as R40.0 across Sleep Disorders guidelines—combines CBT-I behavioral sleep in Excessive sleepiness (somnolence) (R40.0: efficiency tracking) with structured follow-up of Apnea-Hypopnea Index (AHI) [Excessive sleepiness (somnolence) R40.0] (< 5 events/hour (R40.0)).
Pathophysiology, Underlying Causes & Clinical Presentation
At the cellular and tissue level in sleep disorders, Excessive sleepiness (somnolence) (R40.0) involves sympathetic micro-arousals [Excessive sleepiness (somnolence) R40.0]. progression correlates with shifts in Serum Ferritin (Restless in Excessive sleepiness (somnolence) (R40.0: Legs)) (> 75 ng/mL (R40.0)).
Common Symptoms & Clinical Signs
- • Presentation of Excessive sleepiness (somnolence) (R40.0): daytime microsleeps, cognitive in Excessive sleepiness (somnolence) (R40.0: brain fog, or)
- • Secondary Excessive sleepiness (somnolence) clinical sign: prolonged sleep-onset latency [Excessive sleepiness (somnolence) R40.0]
- • Symptom flares in Excessive sleepiness (somnolence) correlating with Serum Ferritin (Restless in Excessive sleepiness (somnolence) (R40.0: Legs)) deviation outside > 75 ng/mL (R40.0)
- • Functional sleep disorders impact requiring CBT-I behavioral sleep in Excessive sleepiness (somnolence) (R40.0: efficiency tracking) evaluation (R40.0)
Primary Federal Reference: NIH / National Library of Medicine MedlinePlus Entry ↗
Excessive sleepiness (somnolence) Diagnostic Classification & Lab Markers
| Metric | Verified Benchmark | Source |
|---|---|---|
| ICD-10-CM Diagnostic Code | R40.0 | WHO / CMS ICD-10-CM Clinical Classification |
| Clinical Specialty Hub | Insomnia, Sleep Apnea & Sleep Health | NIH MedlinePlus Health Topics |
| Diagnostic / Lab Marker: Serum Ferritin (Restless in Excessive sleepiness (somnolence) (R40.0: Legs)) | > 75 ng/mL (R40.0) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: Apnea-Hypopnea Index (AHI) [Excessive sleepiness (somnolence) R40.0] | < 5 events/hour (R40.0) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: Insomnia Severity Index in Excessive sleepiness (somnolence) (R40.0: (ISI)) | < 7 (R40.0) | Clinical Reference Target Range |
FDA-Monographed Medications & Public Cash Price Reference for Excessive sleepiness (somnolence)
| Medication | Pharmacologic Class | Patient Worth-It | CMS NADAC / Unit | Typical Lowest Cash |
|---|---|---|---|---|
| Sodium Oxybate Lumryz, Xyrem • RxCUI 349482 | Central Nervous System Depressant | 92% | $3.5100 | $ 150.66 /mo |
| Solriamfetol Sunosi • RxCUI 2121756 | Dopamine and Norepinephrine Reuptake Inhibitor | 74% | $31.2166 | $ 185.00 /mo |
| Harris Teeter Earwax Removal Drops (Carbamide Peroxide 6.5%) Harris Teeter Earwax Removal Drops • RxCUI 702050-B69256117 | Over-the-Counter Clinical Monograph | 94% | $1.2800 | $ 100.66 /mo |
| Salicylic Acid 10% Salicate • RxCUI RXN-59088214-1776 | FDA Prescription Therapeutic Agent | 80% | $4.9868 | $ 185.00 /mo |
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Excessive sleepiness (somnolence))
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| New Insights on Obstructive sleep apnoea syndrome and left ventricular: What a 5,550-Participant Study Found The present meta-analysis expands previous information on the relationship between OSA and echocardiographic LVH, so far based on individual studies. Journal of hypertension • 2020-09-15 • Meta-Analysis | N = 5,550 | 94/100 | PMID 32371766 ↗ |
| What the Latest Evidence Really Says About Pitolisant versus placebo for excessive daytime sleepiness in narcolepsy and Pitolisant showed great efficacy and controllable security versus placebo for excessive daytime sleepiness in narcolepsy and OSA. Pharmacological research • 2021-05-15 • Meta-Analysis | Multi-cohort | 92/100 | PMID 33667687 ↗ |
| New Insights on Aerobic exercise and resistance training on obstructive sleep: What a 526-Participant Study Found Exercise, including resistance and aerobic training, should be part of treatment for patients with obstructive sleep apnea of all severities, regardless of obesity status, and even for those who are already under continuous... Journal of clinical sleep medicine : JCSM : official publication of the American Academy of Sleep Medicine • 2024-11-01 • Meta-Analysis | N = 526 | 91/100 | PMID 39150699 ↗ |
| New Insights on Clinically relevant effects of solriamfetol on excessive daytime sleepiness: a: What a 231-Participant Study Found A greater percentage of participants treated with solriamfetol achieved normal ESS scores (≤ 10) or clinically meaningful improvements on the ESS compared with those receiving placebo. Journal of clinical sleep medicine : JCSM : official publication of the American Academy of Sleep Medicine • 2021-04-01 • Phase III Randomized Trial | N = 231 | 88/100 | PMID 33226332 ↗ |
| Can This Approach Help? Inside the Latest Research on Long-term study of the safety and maintenance of efficacy of solriamfetol This study demonstrated long-term maintenance of efficacy of solriamfetol under open-label and gold-standard blind, compared against a dummy pill (placebo) conditions. Sleep • 2020-02-13 • Randomized Controlled Trial | Multi-cohort | 88/100 | PMID 31691827 ↗ |
Excessive sleepiness (somnolence) Patient Community & “People Like Me” Threads
Filter Excessive sleepiness (somnolence) community threads and patient logs by age, biological sex, dosage, and treatment duration.